


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. **(Currently Amended)** ~~An entity selected from:~~ **a** compound of Formula (I) :



(I)

and a physiologically functional derivative thereof,

wherein:

R¹ is selected from: hydrogen and C₁₋₄ alkyl which ~~is optionally~~ **optionally** substituted with one or more groups selected from CN and CF₃;

R² is selected from: C₃₋₁₀ unsubstituted alkyl, C₁₋₁₀ alkyl substituted with one or more groups selected from fluorine and CN, C₅-alkenyl, unbranched C₄ alkenyl, and C₁₋₄ alkyl substituted with cycloalkyl; and

R³ is selected from halogen and CN;

~~with the~~ provided ~~proviso~~ that:

(i) when R³ represents Cl, and R¹ represents ethyl, R² is other than propyl;

(ii) when R³ represents Br, and R¹ represents propyl, R² is other than propyl;

(iii) when R³ represents Cl or Br, and R¹ represents butyl, R² is other than butyl; and

(iv) when R¹ represents C₁₋₄ alkyl, CH₂CN, or (CH₂)₃CF₃, R² is other than branched alkyl.

2. **(Currently Amended)** A compound according to claim 1, wherein:

R¹ is selected from: hydrogen, C₁₋₄ alkyl, CH₂CN and (CH₂)₃CF₃;

R² is selected from: C₃₋₁₀ unsubstituted alkyl, (CH₂)₁₋₅CN, C₂₋₅ alkyl with one or more fluorine substitutions, C₅ alkenyl and C₁₋₄ alkyl substituted with cycloalkyl; and


R³ is selected from halogen and CN;

~~with the~~ provided ~~proviso~~ that:

- (i) when R³ represents Cl, and R¹ represents ethyl, R² is other than propyl;
- (ii) when R³ represents Cl or Br and R¹ represents butyl, R² is other than butyl; and
- (iii) when R¹ represents C₁₋₄ alkyl, CH₂CN, or (CH₂)₃CF₃, R² is other than branched alkyl.

- 3. (Currently Amended) A compound according to claim 1, ~~or 2~~ wherein R¹ is selected from: hydrogen and methyl.
- 4. (Currently Amended) A compound according to claim 1, ~~any preceding claim~~ wherein R² is selected from: C₄₋₆ unsubstituted n-alkyl, (CH₂)₁₋₃CN, C₃₋₄ alkyl with one or more fluorine substitutions and C₅ alkenyl.
- 5. (Currently Amended) A compound according to claim 1, ~~any preceding claim~~ wherein R³ ~~represents~~ is halogen.
- 6. (Currently Amended) A compound according to claim 1, ~~any preceding claim~~ wherein R³ is selected from: chlorine and bromine.
- 7. (Currently Amended) A compound according to claim 1, ~~any preceding claim~~ wherein R³ ~~represents~~ is chlorine.
- 8. (Cancelled).
- 9. (Cancelled).
- 10. (Currently Amended) A method for ~~compound according to claim 1 any one of claims 1-7, for use in the~~ treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular ~~disease diseases, disorders of lipid metabolism, including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia~~, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, comprising administration of a compound of Formula (I) according to claim 1.

11. (Currently Amended) ~~An entity selected from:~~ a A compound of Formula (II) :



and a physiologically functional derivative thereof,


wherein:

R¹ is selected from: hydrogen and C₁₋₄ alkyl which may be optionally substituted with one or more groups selected from CN and CF₃;

R² is selected from: C₂₋₁₀ unsubstituted alkyl, C₁₋₁₀ alkyl substituted with one or more groups selected from fluorine and CN, C₅ alkenyl, unbranched C₄ alkenyl, and C₁₋₄ alkyl substituted with cycloalkyl; and R³ is selected from halogen and CN.

~~for use in the manufacture of a medicament for treating diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure or stroke.~~

12. (Currently Amended) A method for the treatment of a human or animal subject having a condition where under-activation of ~~the~~ HM74A receptor contributes to the condition or where activation of the HM74A receptor will be beneficial, which ~~method~~ comprises administering to said human or animal subject an effective amount of ~~an entity selected from:~~ a compound of Formula (II)



and a physiologically functional derivative thereof,

wherein:

R¹ is selected from: hydrogen and C₁₋₄ alkyl which ~~is may be~~ optionally substituted with one or more groups selected from CN and CF₃;

R² is selected from: C₂₋₁₀ unsubstituted alkyl, C₁₋₁₀ alkyl substituted with one or more groups selected from fluorine and CN, C₅ alkenyl, unbranched C₄ alkenyl, and C₁₋₄ alkyl substituted with cycloalkyl; and R³ is selected from halogen and CN.

13. **(Currently Amended)** A method according to claim 12, wherein the human or animal subject has a disorder of lipid metabolism selected from including dyslipidaemia, or hyperlipoproteinaemia or an inflammatory disease or condition.
14. **(Currently Amended)** A pharmaceutical formulation comprising a compound according to claim 1 ~~any one of claims 1-7~~, and one or more physiologically acceptable diluents, excipients or carriers.
15. **(Currently Amended)** A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to claim 1, ~~any one of claims 1-7~~, together with another therapeutically active agent.
16. **(Currently Amended)** A pharmaceutical formulation comprising:
- (i) a compound according to claim 1 ~~any one of claims 1-7~~;
 - (ii) one or more active ingredients selected from statins, fibrates, bile-acid binding resins ~~and~~ or nicotinic acid; and
 - (iii) one or more physiologically acceptable diluents, excipients or carriers.
17. **(Currently Amended)** A method for ~~the~~ preparation of a compound according to claim 1, ~~any one of claims 1-7~~, in which R³ is halogen, wherein the method comprising comprises steps of:
- (i) alkylation at N1 or N3, or dialkylation at N1 and N3 of an N7 protected xanthine;
 - (ii) halogenation at C8; and
 - (iii) de-protection;
- wherein steps (i), (ii) or (iii) are in any order providing de-protection is carried out after alkylation, at N1 or N3 as defined in step (i).
18. **(New)** A method according to claim 10, wherein cardiovascular diseases are selected from atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.

19. **(New)** A method according to claim 10, wherein disorders of lipid metabolism are selected from dyslipidaemia, hyperlipoproteinaemia or inflammatory diseases or conditions.
20. **(New)** A method for treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesterolaemia, cardiovascular diseases, disorders of lipid metabolism type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, comprising administration of a compound of Formula (II) according to claim 11.